Academic Journal
Προβολή σε EDS

Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.
Συγγραφείς: Bang CS; Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea., Kang SJ; Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea., Lim H; Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea., Kim SH; Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea., Lee MW; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea., Nam SY; Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea., Tae CH; Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea., Kim SE; Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea., Kim SY; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea., Jung HK; Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea., Kim BJ; Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea., Choi M; Division of Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea., Jung HY; Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Asan Digestive Disease Research Institute, Seoul, Korea., Kim BW; Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.
Συλλογικό Έργο: Korean College of Helicobacter and Upper Gastrointestinal Research
Πηγή: Helicobacter [Helicobacter] 2026 Jul-Aug; Vol. 31 (4), pp. e70149.
Τύπος έκδοσης: Journal Article; Practice Guideline
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9605411 Publication Model: Print Cited Medium: Internet ISSN: 1523-5378 (Electronic) Linking ISSN: 10834389 NLM ISO Abbreviation: Helicobacter Subsets: MEDLINE
Imprint Name(s): Publication: Oxford : Wiley-Blackwell
Original Publication: Malden, MA : Wiley-Blackwell, c1996-
Ιατρικοί όροι (MeSH): Anti-Bacterial Agents*/therapeutic use , Helicobacter Infections*/diagnosis , Helicobacter Infections*/drug therapy , Helicobacter pylori*/drug effects, Clarithromycin/therapeutic use ; Humans ; Drug Resistance, Bacterial ; Drug Therapy, Combination ; Republic of Korea ; Systematic Reviews as Topic ; Meta-Analysis as Topic
Περίληψη: Background/aims: Since the 2020 Korean guidelines for Helicobacter pylori treatment, clarithromycin resistance rates have risen from 17.8% to 33.3%, dual-priming oligonucleotide-based polymerase chain reaction (DPO-PCR)-based tailored therapy has been adopted, and P-CABs have become available. This fourth revision addresses these changes.
Methods: Nine key questions were addressed through systematic reviews with meta-analyses. Thirteen recommendations were evaluated via modified Delphi process involving 64 experts.
Results: Twelve recommendations achieved first-round consensus; one required revision and achieved 73.9% agreement. Key changes: (1) dual-pillar strategy of tailored therapy and empirical quadruple therapy; (2) restricted use of empirical clarithromycin-based triple therapy under specific conditions; (3) removal of sequential therapy; (4) P-CABs as PPI alternatives; (5) expansion of eradication indications to include gastric cancer prevention in H. pylori gastritis and regression of hyperplastic polyps ≤ 10 mm; and (6) positioning of bismuth quadruple therapy as a conditionally recommended first-line empirical option with preference for reservation as salvage therapy, and introduction of modified bismuth quadruple therapy (addition of bismuth to conventional regimens) as an additional first-line empirical option.
Conclusions: This fourth revised guideline provides updated, evidence-based recommendations for the diagnosis and treatment of H. pylori infection, reflecting the rapidly changing antibiotic resistance landscape and the introduction of new diagnostic and therapeutic tools in Korea. These guidelines aim to assist clinicians, patients, policymakers, and medical educators in optimizing H. pylori management. They may differ from current medical insurance standards and will be revised further based on emerging evidence.
(© 2026 The Author(s). Helicobacter published by John Wiley & Sons Ltd.)
References: Gut. 2016 Sep;65(9):1439-46. (PMID: 26935876)
Gastroenterol Hepatol Bed Bench. 2022 Spring;15(2):172-178. (PMID: 35845300)
Korean J Helicobacter Up Gastrointest Res. 2023 Mar;23(1):34-41. (PMID: 40503379)
Korean J Helicobacter Up Gastrointest Res. 2024 Jun;24(2):143-156. (PMID: 40502844)
Nat Med. 2024 Nov;30(11):3250-3260. (PMID: 39079993)
J Gastroenterol Hepatol. 2020 Oct;35(10):1731-1737. (PMID: 32167605)
Helicobacter. 2023 Feb;28(1):e12940. (PMID: 36458325)
Drugs. 2005;65 Suppl 1:83-96. (PMID: 16335862)
J Clin Med. 2022 Jul 30;11(15):. (PMID: 35956057)
Helicobacter. 2019 Aug;24(4):e12585. (PMID: 30969459)
Gastroenterology. 2016 Jul;151(1):51-69.e14. (PMID: 27102658)
J Natl Cancer Inst. 2006 Jul 19;98(14):974-83. (PMID: 16849680)
Clin Transl Gastroenterol. 2020 Sep;11(9):e00194. (PMID: 33094958)
Helicobacter. 2008 Aug;13(4):282-7. (PMID: 18665938)
Helicobacter. 2026 Mar-Apr;31(2):e70121. (PMID: 41947374)
Gut Liver. 2021 Jul 15;15(4):528-536. (PMID: 33376228)
Korean J Gastroenterol. 2024 Apr 25;83(4):150-156. (PMID: 38659251)
Helicobacter. 2018 Apr;23(2):e12463. (PMID: 29345022)
J Antimicrob Chemother. 2015 Sep;70(9):2447-55. (PMID: 26078393)
Helicobacter. 2019 Oct;24(5):e12654. (PMID: 31411793)
Korean J Helicobacter Up Gastrointest Res. 2025 Mar;25(1):42-47. (PMID: 40550527)
Helicobacter. 2020 Aug;25(4):e12702. (PMID: 32426894)
Am J Gastroenterol. 2016 Dec;111(12):1736-1742. (PMID: 27670603)
Helicobacter. 2026 Jan-Feb;31(1):e70106. (PMID: 41531249)
Dig Liver Dis. 2018 Feb;50(2):139-141. (PMID: 29089267)
Br J Clin Pharmacol. 2012 Jan;73(1):140-3. (PMID: 21689141)
BMJ. 2008 Apr 26;336(7650):924-6. (PMID: 18436948)
Am J Gastroenterol. 2024 Sep 1;119(9):1730-1753. (PMID: 39626064)
Gut. 2019 Sep;68(9):1545-1575. (PMID: 31278206)
JAMA. 2004 Jan 14;291(2):187-94. (PMID: 14722144)
Aliment Pharmacol Ther. 2022 Aug;56(3):436-449. (PMID: 35665947)
Korean J Intern Med. 2023 Jul;38(4):493-503. (PMID: 37369525)
Aliment Pharmacol Ther. 2012 Jan;35(2):209-21. (PMID: 22129228)
Clin Gastroenterol Hepatol. 2014 Feb;12(2):177-86.e3; Discussion e12-3. (PMID: 23751282)
Helicobacter. 2019 Aug;24(4):e12592. (PMID: 31111572)
Helicobacter. 2024 Sep-Oct;29(5):e13143. (PMID: 39434634)
Gut. 2025 Oct 8;74(11):1767-1791. (PMID: 40912906)
Helicobacter. 2020 Apr;25(2):e12679. (PMID: 31958193)
J Clin Gastroenterol. 2020 Jul;54(6):522-527. (PMID: 32028286)
Gut Liver. 2023 Sep 15;17(5):722-730. (PMID: 36168964)
Helicobacter. 2007 Feb;12(1):31-5. (PMID: 17241298)
Korean J Gastroenterol. 2023 Jul 25;82(1):10-17. (PMID: 37489077)
Gut Liver. 2018 Nov 15;12(6):648-654. (PMID: 30037167)
Scand J Gastroenterol. 2021 Sep;56(9):1017-1022. (PMID: 34369255)
Helicobacter. 2023 Jun;28(3):e12977. (PMID: 37083222)
Gastroenterology. 2021 Apr;160(5):1831-1841. (PMID: 33524402)
Dig Dis. 2024;42(4):292-298. (PMID: 38599188)
Gastroenterology. 2024 Nov;167(6):1228-1238. (PMID: 39269391)
Ther Adv Gastroenterol. 2024 Dec 27;17:17562848241309870. (PMID: 39741655)
Indian J Gastroenterol. 2025 Dec 18;:. (PMID: 41413744)
Korean J Lab Med. 2010 Aug;30(4):381-7. (PMID: 20805710)
J Infect Dis. 2023 Aug 31;228(5):511-518. (PMID: 37079894)
Gastroenterol Hepatol (N Y). 2022 Dec;18(12):693-700. (PMID: 36865588)
J Clin Med. 2021 Jun 14;10(12):. (PMID: 34198677)
Gut Microbes. 2020 Sep 2;11(5):1314-1323. (PMID: 32362221)
Helicobacter. 2009 Feb;14(1):22-8. (PMID: 19191892)
Gut Liver. 2025 May 15;19(3):364-375. (PMID: 40289740)
Gut. 2025 Sep 8;74(10):1561-1570. (PMID: 40645767)
Front Med (Lausanne). 2023 Mar 22;10:1150396. (PMID: 37035320)
Helicobacter. 2024 May-Jun;29(3):e13098. (PMID: 38853394)
N Engl J Med. 2020 Jan 30;382(5):427-436. (PMID: 31995688)
Helicobacter. 2010 Feb;15(1):1-20. (PMID: 20302585)
J Clin Gastroenterol. 2023 Feb 01;57(2):111-126. (PMID: 36598803)
Helicobacter. 2025 Jan-Feb;30(1):e70011. (PMID: 39902743)
Helicobacter. 2023 Feb;28(1):e12939. (PMID: 36478622)
Gastroenterology. 2022 Sep;163(3):608-619. (PMID: 35679950)
J Gastroenterol. 2023 Dec;58(12):1167-1177. (PMID: 37777987)
Biol Pharm Bull. 2024;47(8):1405-1414. (PMID: 39085080)
Clin Transl Gastroenterol. 2025 Feb 01;16(2):e00792. (PMID: 39620581)
World J Gastroenterol. 2024 Feb 14;30(6):556-564. (PMID: 38463026)
Microb Pathog. 2018 Apr;117:23-26. (PMID: 29428426)
Lancet. 2016 Nov 12;388(10058):2355-2365. (PMID: 27769562)
J Gastroenterol Hepatol. 2020 Apr;35(4):617-623. (PMID: 31758571)
Helicobacter. 2019 Dec;24(6):e12660. (PMID: 31507036)
Ann Intern Med. 1998 Nov 1;129(9):712-5. (PMID: 9841603)
Gut. 2012 Jun;61(6):812-8. (PMID: 21917649)
J Dig Dis. 2022 Oct;23(10):561-567. (PMID: 36321440)
Antibiotics (Basel). 2024 Mar 20;13(3):. (PMID: 38534715)
Helicobacter. 2024 May-Jun;29(3):e13084. (PMID: 38717034)
Dig Liver Dis. 2016 Aug;48(8):899-903. (PMID: 27211882)
Dig Dis Sci. 2020 Dec;65(12):3652-3659. (PMID: 31974914)
BMJ. 2016 Oct 12;355:i4919. (PMID: 27733354)
World J Gastroenterol. 2014 Jun 7;20(21):6547-53. (PMID: 24914376)
PLoS One. 2020 Dec 30;15(12):e0244500. (PMID: 33378403)
J Coll Physicians Surg Pak. 2021 Feb;31(2):128-131. (PMID: 33645176)
Gastroenterology. 2018 Oct;155(4):1109-1119. (PMID: 29964036)
Nat Rev Gastroenterol Hepatol. 2013 Aug;10(8):495-500. (PMID: 23752823)
Gut. 2004 Sep;53(9):1244-9. (PMID: 15306578)
BMC Gastroenterol. 2024 Apr 12;24(1):131. (PMID: 38609893)
Dig Dis Sci. 2022 Apr;67(4):1222-1230. (PMID: 33755825)
Gastroenterology. 2025 Apr;168(4):848-849. (PMID: 39848604)
J Pak Med Assoc. 2024 Mar;74(3):432-435. (PMID: 38591272)
J Natl Cancer Inst. 2000 Dec 6;92(23):1881-8. (PMID: 11106679)
Scand J Gastroenterol. 2003 Aug;38(8):904. (PMID: 12940447)
Can J Gastroenterol Hepatol. 2017;2017:4385161. (PMID: 28349044)
Digestion. 2015;92(2):55-9. (PMID: 26183105)
Ther Adv Gastroenterol. 2025 Jan 31;18:17562848251314801. (PMID: 39898357)
Am J Gastroenterol. 2021 Jun 1;116(6):1220-1229. (PMID: 33840725)
J Clin Med. 2019 Dec 25;9(1):. (PMID: 31881688)
Health Sci Rep. 2023 Oct 04;6(10):e1593. (PMID: 37808931)
World J Gastroenterol. 2019 Dec 14;25(46):6743-6751. (PMID: 31857776)
World J Gastroenterol. 2006 Mar 21;12(11):1770-3. (PMID: 16586550)
World J Gastroenterol. 2021 Aug 21;27(31):5247-5258. (PMID: 34497448)
BMJ. 2019 Aug 28;366:l4898. (PMID: 31462531)
BMJ Open Gastroenterol. 2020 Sep;7(1):. (PMID: 32883715)
Korean J Gastroenterol. 2013 Jul;62(1):3-26. (PMID: 23954956)
Chin Med J (Engl). 2023 Jul 20;136(14):1690-1698. (PMID: 37469024)
Gut Liver. 2021 Mar 15;15(2):168-195. (PMID: 33468712)
World J Clin Cases. 2022 Jul 6;10(19):6349-6359. (PMID: 35979311)
Int J Antimicrob Agents. 2024 Nov;64(5):107320. (PMID: 39293772)
J Infect Dis. 2013 Oct 1;208(7):1123-30. (PMID: 23801607)
Helicobacter. 2024 Nov-Dec;29(6):e70003. (PMID: 39628413)
Helicobacter. 2008 Dec;13(6):542-9. (PMID: 19166420)
J Gastroenterol Hepatol. 1998 Jan;13(1):1-12. (PMID: 9737564)
Korean J Helicobacter Up Gastrointest Res. 2026 Jun;26(2):164-188. (PMID: 42316523)
World J Gastroenterol. 2019 Dec 14;25(46):6790-6798. (PMID: 31857780)
Korean J Intern Med. 2018 May;33(3):506-511. (PMID: 29232943)
Helicobacter. 2025 Sep-Oct;30(5):e70081. (PMID: 41116600)
Korean J Helicobacter Up Gastrointest Res. 2026 Mar;26(1):23-36. (PMID: 41846442)
Aliment Pharmacol Ther. 2011 Nov;34(9):1098-105. (PMID: 21923713)
J Natl Cancer Inst. 2012 Mar 21;104(6):488-92. (PMID: 22271764)
BMC Gastroenterol. 2011 Oct 17;11:112. (PMID: 22004003)
Indian J Gastroenterol. 2019 Aug;38(4):325-331. (PMID: 31520370)
Helicobacter. 2007 Aug;12(4):275-8. (PMID: 17669098)
J Gastroenterol Hepatol. 2019 Apr;34(4):700-706. (PMID: 30011083)
JMIR Res Protoc. 2025 Jul 15;14:e72228. (PMID: 40663770)
Scand J Gastroenterol. 2015;50(10):1185-90. (PMID: 25881966)
Aliment Pharmacol Ther. 2016 Sep;44(5):427-37. (PMID: 27363687)
Helicobacter. 2023 Oct;28(5):e13003. (PMID: 37565458)
Medicine (Baltimore). 2015 Nov;94(47):e2056. (PMID: 26632710)
World J Gastroenterol. 2012 May 21;18(19):2377-82. (PMID: 22654429)
Microorganisms. 2025 Feb 26;13(3):. (PMID: 40142411)
Helicobacter. 2024 Jul-Aug;29(4):e13126. (PMID: 39143948)
BMJ. 2019 Sep 11;366:l5016. (PMID: 31511230)
BMC Microbiol. 2023 May 27;23(1):155. (PMID: 37237357)
J Gastroenterol. 2023 Jul;58(7):633-641. (PMID: 37042991)
Gastroenterology. 2018 Aug;155(2):347-354.e9. (PMID: 29723507)
Lancet Gastroenterol Hepatol. 2023 Mar;8(3):228-241. (PMID: 36549320)
Chin Med J (Engl). 2014;127(8):1454-8. (PMID: 24762588)
Gut. 2022 Aug 11;71(9):1724-1762. (PMID: 35944925)
J Gastrointestin Liver Dis. 2011 Sep;20(3):299-304. (PMID: 21961099)
Bosn J Basic Med Sci. 2016 Jan 01;16(1):52-7. (PMID: 26773183)
Am J Gastroenterol. 1996 Apr;91(4):714-7. (PMID: 8677935)
Am J Gastroenterol. 1995 Dec;90(12):2152-9. (PMID: 8540506)
Korean J Gastroenterol. 2016 Nov 25;68(5):260-264. (PMID: 27871162)
Helicobacter. 2025 Nov-Dec;30(6):e70101. (PMID: 41454437)
Ter Arkh. 2019 Aug 15;91(8):28-33. (PMID: 32598751)
Gut. 2015 Sep;64(9):1353-67. (PMID: 26187502)
Helicobacter. 2014 Dec;19(6):455-61. (PMID: 25231089)
Korean J Gastroenterol. 2008 May;51(5):285-90. (PMID: 18516012)
Gut. 2024 Dec 10;74(1):15-25. (PMID: 39461739)
J Antimicrob Chemother. 2018 Sep 1;73(9):2510-2518. (PMID: 29846605)
Turk J Gastroenterol. 2023 Mar;34(3):221-226. (PMID: 36511603)
Chin Med J (Engl). 2022 Dec 20;135(24):2899-2910. (PMID: 36579940)
J Prev Med Public Health. 2025 Jul;58(4):337-347. (PMID: 40575987)
Indian J Gastroenterol. 2022 Dec;41(6):627-633. (PMID: 36573961)
Expert Rev Anti Infect Ther. 2022 Jun;20(6):923-929. (PMID: 34883037)
J Korean Med Sci. 2020 Feb 10;35(5):e33. (PMID: 32030921)
Drugs. 2024 Mar;84(3):319-327. (PMID: 38388872)
Eur J Gastroenterol Hepatol. 2016 Apr;28(4):449-54. (PMID: 26735158)
Gut Liver. 2016 Jul 15;10(4):556-61. (PMID: 27114421)
J Gastroenterol Hepatol. 2021 Dec;36(12):3308-3313. (PMID: 34622504)
Gastroenterology. 2022 Jul;163(1):154-162.e3. (PMID: 35364066)
Medicine (Baltimore). 2022 Aug 19;101(33):e30069. (PMID: 35984159)
Gut Liver. 2022 Jul 15;16(4):535-546. (PMID: 35791797)
BMC Gastroenterol. 2022 Feb 19;22(1):70. (PMID: 35183117)
Grant Information: RS-2025-02304642 Patient-Centered Clinical Research Coordinating Center
Contributed Indexing: Keywords: Helicobacter pylori; antibiotic resistance; clinical practice guideline; potassium‐competitive acid blocker; tailored therapy
Substance Nomenclature: 0 (Anti-Bacterial Agents)
H1250JIK0A (Clarithromycin)
Entry Date(s): Date Created: 20260713 Date Completed: 20260713 Latest Revision: 20260813
Update Code: 20260814
PubMed Central ID: PMC13359576
DOI: 10.1111/hel.70149
PMID: 42439470
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1523-5378
DOI:10.1111/hel.70149